Integra Lifesciences Holdings (IART) EBITDA (2009 - 2026)

Integra Lifesciences Holdings has disclosed EBITDA across 18 years of filings, most recently posting $19.3 million for Q2 2026.

• In Q2 2026, EBITDA rose 103.76% year-over-year to $19.3 million; the TTM figure through Jun 2026 stood at $65.6 million (up 113.09% YoY), while the FY2025 annual figure was -$493.4 million, down 1836.55% from the prior year.
• EBITDA came in at $19.3 million for Q2 2026 at Integra Lifesciences Holdings, up from $11.5 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $67.8 million in Q4 2022 to a low of -$512.7 million in Q2 2025.
• Average EBITDA over 5 years is -$4.7 million, with a median of $21.2 million recorded in 2025.
• The largest YoY upside for EBITDA was 244.31% in 2025 against a maximum downside of 16825.52% in 2025.
• Over 5 years, EBITDA stood at $67.8 million in 2022, then sank by 46.86% to $36.0 million in 2023, then decreased by 1.17% to $35.6 million in 2024, then plunged by 35.33% to $23.0 million in 2025, then fell by 16.3% to $19.3 million in 2026.
• Per Business Quant data, the three most recent EBITDA figures were $19.3 million in Q2 2026, $11.5 million in Q1 2026, and $23.0 million in Q4 2025.